110751-41-2

Upstream product

• 91958-13-3 methyl 2-allyloxy-4-acetylaminobenzoate 
• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 

Downstream Products

• 202664-60-6 4-Acetylamino-3-allyl-2-ethoxy-benzoic acid methyl ester 
• 124911-65-5 methyl 2-methoxymethyloxy-3-allyl-4-acetylaminobenzoate 
• 627531-28-6 4-Acetylamino-2-hydroxy-3-(3-hydroxypropyl)-benzoic acid, methyl ester 
• 202664-64-0 4-Acetylamino-5-chloro-2-ethoxy-3-propyl-benzoic acid methyl ester 
• 143878-29-9 4-acetamido-5-chloro-2,3-dihydrobenzofuran-7-carboxylic acid methyl ester 
• 202664-62-8 4-Acetylamino-5-chloro-2-methoxy-3-propyl-benzoic acid methyl ester 
• 202664-59-3 4-Acetylamino-2-methoxy-3-propyl-benzoic acid methyl ester 
• 149466-67-1 methyl 4-acetylamino-2,3-dihydrobenzo[b]furan-7-carboxylate 
• 202664-85-5 methyl 4-acetylamino-2-hydroxy-3-(2-hydroxyethyl)benzoate 
• 202664-83-3 4-(acetylamino)-2-hydroxy-3-(2-oxoethyl)benzoic acid methyl ester 
• 175422-56-7 4-Amino-5-chloro-2-ethoxy-3-propyl-benzoic acid 
• 175422-55-6 4-Amino-5-chloro-2-methoxy-3-propyl-benzoic acid 
• 123654-26-2 4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylic acid 
• 202664-58-2 4-Acetylamino-3-allyl-2-methoxy-benzoic acid methyl ester 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of 3-substituted benzamide, benzo[b]furan-7-carboxamide, 2,3-dihydrobenzo[b]furan-7- carboxamide, and indole-5-carboxamide derivatives as selective serotonin 5- HT4 receptor agonists

The title compounds (6-9) were prepared and evaluated for serotonin 5- HT4 agonistic activity in in vitro tests. Introducing a propyl or allyl group at the 3-position of benzamide caused only a slight enhancement of agonistic activity. Construction of the benzo[b']furan skeleton and 2,3- dihydrobenzo[b]furan skeleton caused a significant enhancement of the activity. 4-Amino-N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-5-chloro-2- methylbenzo[b]furan-7-carboxamide (7b) hemifumarate was as potent as cisapride. 4-Amino-N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-5-chloro-2,3- dihydro-2-methylbenzo[b]furan-7-carboxamide (8a) hemifumarate, 4-amino-N-[2- (1-azabicyclo [3.3.0]octan-5-yl)ethyl]5-chloro-2,3-dihydro-2- ethylbenzo[b]furan-7-carboxamide (8c) hemifumarate, and 4-amino-N-]2-(1- azabicyclo[3.3.0]octan-5-yl]-5-chloro-2,3-dihydro-2,3-dimethylhenzo[b]furan- 7-carboxamide (8d) hemifumarate were more potent than cisapride. Furthermore, 8a hemifumarate was free from dopamine D1, D2, serotonin 5-HT1, 5-HT2 and muscarine M1, M2 receptor binding activity in the in vitro tests. On the other hand, construction of the indole skeleton caused a remarkable decrease in activity.

Quinuclidyl benzoxepins as 5-HT3 antagonists

Certain specific substituted 9-N-(1-azabicyclo-[2.2.2.]octan-3-yl)carboxamido-2,3,4,5-tetrahydro-1-benzoxepins and their valuable use as 5-HT3 antagonists having CNS and gastric prokinetic acticity and void of any significant D2 receptor binding properties are disclosed. Methods for their preparation also are described.